Supplemental Material

ASMase is Essential for the Immune Response to Partial-Tumor Radiation Exposure

Mickael Mathieu[a,b] Prerna R. Nepali[b] James Russell[c] Hadi Askarifirouzjaei[b] Melis Baltaci[b] Simon N. Powell[b] John Humm[c] Joseph O. Deasy[c] Adriana Haimovitz-Friedman[b*]

[a]Clinical Research Unit, Emile Roux Hospital Center, Le Puy-en-Velay, France, [b]Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA, [c]Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA



Supp Fig 1: Schematic of full irradiation and partial volume RT
The irradiation field was defined using GAF chromic film, and the mouse was positioned so that either all or half of the tumor was in the field. The part of the tumor that was outside of the irradiation field (OF) received a dose of less than 5% of the primary in-field (IF) dose.



Supp Fig 2: Efficient PMN depletion in tumors with a-Ly6G treatment

(A) Representative Ly6G-stained images with Hematoxylin counterstained nuclei for the unirradiated control tumors of LLC-bearing C57BL6 mice treated with a-IgG2a or a-Ly6G antibodies. Mice were sacrificed after a week of treatment. Staining performed by the molecular cytology core facility in MSKCC. (B) Quantification of the Ly6G-positive cells/Region of interest (ROI) from a representative experiment with 6 mice per treatment group.

Statistical analysis: Student's T-test with Welch's correction on the area of the positive signal compared to the total area for each group: ** p-value < 0.01.